Presentation Personalized Medicine Consortium
-
Upload
eurobioforum -
Category
Health & Medicine
-
view
732 -
download
5
description
Transcript of Presentation Personalized Medicine Consortium
Personalized Medicine Consortium:
Big Science in a Small Country
Luxinnovation Conference:
Business Meets Research
26 May 2011
FOR NEXT GENERATION HEALTHCARE
2008 – Luxembourg Creates New Research
Program in Personalized Medicine
Luxembourg
• Luxembourg Centre for
Systems Biomedicine
• Integrated Biobank of
Luxembourg – IBBL
• Lung Cancer
U.S. Partner
• Institute for Systems
Biology (Seattle)
• TGen – Arizona Research
Centre
• Program in Personalized
Medicine – Consortium of
several U.S. centres
Small is beautiful
• Luxembourg has the potential to be a world leader in testing
and implementing new advances in personalized medicine into
its health care system
• 5 hospitals, no medical school, 1 university
• Small, but excellent scientific community – very collegial and
embraces partnerships
• Different Ministries work closely together on personalized
medicine initiative
• Ministry of Health believes that research will improve health
• Introduction of new innovation involves only one level of
government
• September 2010 – Leaders of the three Luxembourg programs agree to
support a major coordinated initiative in personalized medicine focused
on four priority research areas:
– Cancer (lung, colon, and breast)
– Type 2 diabetes
– Parkinson’s disease
– Large population cohort
• Agree to apply a systems biology approach to all research
initiatives in personalized medicine
• Coordinate activities through creation of a Personalized Medicine
Consortium to bring together all of the key stakeholders under
one umbrella
Evolution of Personalized
Medicine Consortium (PMC)
Organization of PMC
Cancer Diabetes
LNS
CRP-SantéPPM/CIEC
IBBL (TGen)
LCSB (ISB)
Parkinson’sDisease
HealthEconomics
Normal Cohort
PMC
Composition of PMC
• Leaders of each program in
personalized medicine
• Leaders from each major partner
• CIEC
• Health economics
• Laboratoire National de Santé
• US partners represented by their
Luxembourg partner
• IBBL accepts responsibility for the
budget of PMC and for coordination
• PMC meets monthly
• Decisions made by consensus
Personalized Medicine - Now
Hospital and
Pathology labs
Patient Doctor
Results
Diagnosis
Disease
Tissue
Examine
Treatment
Symptom information
Personalized Medicine – Future
Patient Doctor
Summary DataTissue
Examine
Molecular
Diagnosis
+
Recommended
Treatments
Molecular
Diagnostic lab
Best Treatment
Clinical Data
Data
Warehouse
Informatics
Centre
Data
Molecular
analysisDiagnosis
Components of Personalized
Medicine Initiative
1. Excellent, multidisciplinary research teams
a) focused on specific problems using systems biology
b) conduct the innovative research
c) coordinate the clinical testing of novel interventions.
2. Sophisticated technology platforms
a) collect high quality tissue and clinical data
b) high through-put technologies generate the large datasets
required by the teams.
3. State-of-the-art informatics
a) conduct informatics research
b) support the disease teams for data mining, data analysis and
model building.
Biorepository & Molecular
Diagnostic labs
Data
Warehouse
Informatics
Centre
IBBL and PMC
IBBL, PMC and Personalized Medicine
Hospital and
Pathology labs
Patient Doctor
Tissue
Treatment
Diagnosis
Disease
Results
Examine
Symptom information
PMC
Research
Team
Possible
Molecular
DiagnosisResearch
Results
De-identified
Clinical Data
Patient Data
Trusted
Third Party
(ebrc)
Discuss
Findings
Discuss
Findings
Molecular
analyses
Data
Mining
Research
Plans
Current Status of PMC
• Research teams created for cancer, diabetes
and Parkinson’s disease – cohort will be
organized by end of summer
• Cancer and Parkinson’s groups have defined
their research agenda – Diabetes has draft plan
• All teams looking for partners – both public and
private sector
Questions and Comments